Aminoglutethimide (with hydrocortisone) induced agranulocytosis in primary breast cancer.
作者信息
Vincent M D, Clink H M, Coombes R C, Smith I E, Kandler R, Powles T J
出版信息
Br Med J (Clin Res Ed). 1985 Jul 13;291(6488):105-6. doi: 10.1136/bmj.291.6488.105-a.
Abstract
摘要
相似文献
1
Aminoglutethimide (with hydrocortisone) induced agranulocytosis in primary breast cancer.氨鲁米特（联合氢化可的松）在原发性乳腺癌中诱发了粒细胞缺乏症。
Br Med J (Clin Res Ed). 1985 Jul 13;291(6488):105-6. doi: 10.1136/bmj.291.6488.105-a.
2
Agranulocytosis induced by aminoglutethimide.氨鲁米特诱发的粒细胞缺乏症。
Acta Clin Belg. 1988;43(2):146-8. doi: 10.1080/17843286.1988.11717923.
3
Pancytopenia induced by aminoglutethimide in the treatment of breast cancer.氨鲁米特治疗乳腺癌所致的全血细胞减少
Cancer Treat Rep. 1978 Oct;62(10):1581-3.
4
Aminoglutethimide induced agranulocytosis in breast cancer.氨鲁米特可诱发乳腺癌患者出现粒细胞缺乏症。
Br Med J (Clin Res Ed). 1985 Oct 5;291(6500):970-1. doi: 10.1136/bmj.291.6500.970-b.
5
Agranulocytosis associated with aminoglutethimide: pharmacological and marrow studies.与氨鲁米特相关的粒细胞缺乏症：药理学与骨髓研究
Br J Cancer. 1986 Jul;54(1):119-22. doi: 10.1038/bjc.1986.160.
6
A randomized phase II trial of aminoglutethimide and hydrocortisone versus combined aminoglutethimide, hydrocortisone and fluoxymesterone in advanced breast cancer.氨鲁米特与氢化可的松联合应用对比氨鲁米特、氢化可的松及氟羟甲睾酮联合应用治疗晚期乳腺癌的随机II期试验。
Radiother Oncol. 1987 Jul;9(3):217-20. doi: 10.1016/s0167-8140(87)80233-5.
7
Aminoglutethimide-induced myelosuppression.氨鲁米特诱导的骨髓抑制。
Breast Cancer Res Treat. 1986;7(3):211-2. doi: 10.1007/BF01806252.
8
[Aminoglutethimide in advanced breast cancer. Multicenter trial comparing 500 mg and 1000 mg per day].
Acta Clin Belg Suppl. 1986;11:41-8.
9
Aminoglutethimide as second line therapy in advanced breast cancer.
Breast Cancer Res Treat. 1986;7 Suppl:S51-4.
10
Clinical studies with aminoglutethimide in advanced breast carcinoma.氨鲁米特用于晚期乳腺癌的临床研究。
Acta Clin Belg Suppl. 1986;11:29-40.
引用本文的文献
1
Idiosyncratic Drug-Induced Neutropenia and Agranulocytosis in Elderly Patients.老年患者的特异质性药物诱导的中性粒细胞减少症和粒细胞缺乏症
J Clin Med. 2020 Jun 10;9(6):1808. doi: 10.3390/jcm9061808.
2
Neutropenia induced by aminoglutethimide in breast cancer.氨鲁米特诱导的乳腺癌中性粒细胞减少症。
J R Soc Med. 1993 Aug;86(8):480-1. doi: 10.1177/014107689308600819.
3
Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.氨鲁米特作为乳腺癌内分泌治疗的作用机制
Drugs. 1988 Jun;35(6):685-710. doi: 10.2165/00003495-198835060-00005.
4
4-hydroxyandrostenedione--further clinical and extended endocrine observations.4-羟基雄烯二酮——进一步的临床及扩展内分泌观察
Br J Cancer. 1990 Aug;62(2):309-13. doi: 10.1038/bjc.1990.284.
5
Aromatase inhibitors in malignant diseases of aging.芳香化酶抑制剂在衰老相关恶性疾病中的应用
Drugs Aging. 1992 Nov-Dec;2(6):530-45. doi: 10.2165/00002512-199202060-00008.
本文引用的文献
1
Leukopenia associated with aminoglutethimide therapy: a case report.氨鲁米特治疗相关的白细胞减少症：一例报告
Cancer Treat Rep. 1982 Oct;66(10):1879.
2
Skin tags and colonic polyps.
Ann Intern Med. 1984 Jan;100(1):159-60. doi: 10.7326/0003-4819-100-1-159_2.
3
Pancytopenia induced by aminoglutethimide in the treatment of breast cancer.氨鲁米特治疗乳腺癌所致的全血细胞减少
Cancer Treat Rep. 1978 Oct;62(10):1581-3.
Zotero 插件